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OBJECTIVES: The CAPRIE study has demonstrated an
8.7% relative risk reduction (RRR) for atherothrombotic
events (vascular death, myocardial infarction, ischemic
stroke) compared with aspirin (ASA) in patients with
symptomatic atherothrombotic disease. The objective of
this study was to assess the cost-effectiveness of clopido-
grel relative to ASA for secondary prevention of ischemic
events in the Netherlands. METHODS: The cost-
effectiveness, in terms of cost per life-year saved, was
determined with a Markov model in which patients were
divided according to vascular events and time from last
event. Effectiveness data were derived from the CAPRIE
study; long-term outcomes were based on epidemiologi-
cal estimates concerning age speciﬁc event rates and case
fatality rates. Direct costs were updated from previous
studies, indirect costs were disregarded due to the age of
the patients. Discount rate was 4% for both costs and
effects. RESULTS: Compared with aspirin, using event-
speciﬁc risk reductions, 1-year treatment with clopidogrel
costs €743 more with a gain in life-years and quality
adjusted life-years (QALY’s) of 0.033 and 0.043 respec-
tively. Using a constant RRR of 8.7%, the results were
consistent providing a cost per life-year saved of €19.462
and a cost per QALY of €15.779. Sensitivity analyses
revealed that uncertainties surrounding the outcomes are
mainly driven by the expected effectiveness, most notably
when deﬁning sub-groups. The higher the risk for events,
the better the cost-effectiveness ratio. In comparison to
no treatment (ASA intolerance or previous failure) clopi-
dogrel is expected to combine gain in effectiveness (0.158
life years, 0.210 QALY’s) with savings (€332 per patient).
CONCLUSIONS: Clopidogrel is a dominant strategy in
patients not eligible for treatment with ASA. The cost
effectiveness is within an acceptable range when com-
pared with ASA, especially in high-risk patients.
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OBJECTIVES: Idiopathic dilated cardiomyopathy
(DCM) is a life threatening heart disease and major
reason for heart transplantation. Short time medical efﬁ-
cacy of immunoadsorption (IA) for DCM-patients has
been demonstrated in ﬁrst clinical studies. Objective 
of this study was to determine 5-year survival rates and
direct medical costs to calculate costs per life year gained
from a societal perspective. METHODS: Based on a pre-
viously published matched case-control study with clini-
cal endpoints 34 patients of similar age, sex, duration 
and severity of DCM were included. Inpatient hospital
costs of initial hospital stay were calculated from data
extracted from patients’ ﬁles and hospital’s internal
costing. Patients and treating cardiologists were con-
tacted, thus determining resource use for primary and
specialist’s outpatient care, inpatients hospital stays and
drugs during follow up. RESULTS: Patients treated with
IA show a highly signiﬁcant better survival: 5-year sur-
vival rate was 82% compared to 41%, Logrank statistics
after Kaplan-Meier analysis p = 0,0071. Cost for IA were
€28.400 per patient. Five-year medical costs were
€118,600 per patient of IA group and €75,500 in con-
trols; the costs per year of survival were €24,900 in IA
group respectively €28,900 in controls. Incremental costs-
effectiveness was €34,365 per life year gained. CON-
CLUSIONS: For the ﬁrst time in a matched controlled
study design survival analysis and economic evaluation of
this new emerging technology for patients with DCM
were performed. Although high initial treatment costs for
IA occur the signiﬁcantly better survival leads to reason-
able costs per LYG.
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OBJECTIVE: To investigate the use of resources and cost
implications of stroke prophylaxis with warfarin for
patients with non-valvular atrial ﬁbrillation (NVAF) 
in clinical practice. METHODS: All new patients with
NVAF referred to anticoagulation clinic over a recruit-
ment period of 21 months were studied. Patients were
interviewed personally on their ﬁrst visit then by tele-
phone call every 4–6 weeks for a mean (SD) of 19 (8.1)
months, range (10 to 31 months). They were asked about
any bleeding events or bleeding related extra doctor’s
visits, procedures or hospital admissions. We also
inquired about the method and the cost of transport to
the anticoagulation clinic, time off work for the patient
and/or his carer and the costs involved. Costs of warfarin
treatment were viewed as: a) cost of the drug; b) cost of
INR monitoring (analysis, travelling, nurse visits, time off
work, and postage); and c) and the costs associated with
bleeding (bleeding related extra-doctors visits or hospital
admissions). RESULTS: A total of 402 patients were
included. Mean (SD) age was 72.3 (10.3) years and 224
654 Abstracts
(56%) patients were men. Annual event rates were 1.7%,
(95% CI 0.4–3.0) for major bleeding, 16.6%, (95% CI
13.0–20.2) for minor bleeding. Mean cost of warfarin
treatment per patient per month was £11.0 (95% CI
10.2–11.6) in patients with no bleeding and £11.9 (95%
CI 10.3–12.5) in patients with minor bleeding (p =
0.095), while in patients with major bleeding the cost was
signiﬁcantly higher (£299.0, 95% CI 74.6–538.9, p =
0.0001). Total cost of warfarin treatment per patient per
year was £159.4 and cost to prevent one stroke per year
was £5260.2. CONCLUSIONS: Warfarin treatment was
cost-effective relative to the costs of stroke. This is likely
to be more cost effective in older people because they have
a higher incidence of stroke.
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OBJECTIVES: Rosuvastatin, a new HMG-CoA reductase
inhibitor has been shown to signiﬁcantly reduce LDL cho-
lesterol. The objective to this analysis was to assess the
cost-effectiveness of rosuvastatin compared to all statins
currently available in Greece. METHODS: A cost-
effectiveness model was developed to compare rosuvas-
tatin with atorvastatin, pravastatin, simvastatin and ﬂu-
vastatin over 52-weeks, from the perspective of the Greek
health care system. Effectiveness was deﬁned as the per-
centage of patients reaching European targets and was
derived from a simulation of clinical trials data. Clinical
practice patterns were derived from a survey among lipid
treatment hospital centers. Patients received a 12-week
prescription of the licensed starting dose. If LDL-C
exceeded the target (3.0mmol/L), patients are titrated to
a higher dose of statin every 12 weeks until they achieve
target or the maximum dose is reached. Patients reaching
target (responders), remain at the last prescribed dose,
followed-up every six months. Only direct medical costs
were included. However, Greek patients can freely use
public or private providers, so both public and private
charges were used. Drug cost estimates are based on rosu-
vastatin expected, and on other statins’ current, ex-
factory prices. Budgetary impact estimates were based on
a hypothesized rosuvastatin market share. RESULTS:
More rosuvastatin-treated patients reach target with the
starting dose. Rosuvastatin patients need fewer up-titra-
tion visits and incur lower costs per responder in their
ﬁrst year of treatment compared to atorvastatin, pravas-
tatin, simvastatin and ﬂuvastatin. Rosuvastatin is more
effective and less costly across the available dose ranges.
For a cohort of 10,000 patients, if rosuvastatin where to
have a 25% market share, the model calculates that there
would be 642 additional responders, reducing annual
costs by €728.204,72 and €83.372,08 in private and
public charges respectively. CONCLUSIONS: Rosuvas-
tatin has been demonstrated to be more effective and a
potentially cost-saving therapy for Greek patients.
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OBJECTIVE: To determine the incremental cost-
effectiveness ratio (ICER) of a new antiplatelet agent,
clopidogrel versus no treatment, in secondary prevention
of atherothrombotic events (myocardial infarction,
ischemic stroke, vascular death) in patients for whom
ASA is not a relevant therapeutic strategy in Hungary.
METHODS: A Markov model designed with 7 clinical
states was used to project the ICER as the cost needed to
achieve an extra life year with clopidogrel compared to
no treatment with a time horizon of 2 years. Based on
Fisher’s analysis the model has combined the rates of 
clinical outcomes reported in CAPRIE (clopidogrel arm)
and in the Antiplatelet Trialists’ Collaboration (no treat-
ment arm) with survival data derived from the Framing-
ham database. Costs of atherothrombotic outcomes were
assessed from Hungarian sources. Payer perspective
(Insurer) was used. The ICER was calculated for patients
who could not take ASA (because of intolerance, allergic
or non responders to ASA). A discount rate of 5% was
applied to both costs and beneﬁts. RESULTS: When com-
pared to no treatment 58 events are avoided per 1000
patients treated with clopidogrel which translates into
297 life years gained. The incremental cost is 241,998
HUF (€968). The ICER of clopidogrel versus no treat-
ment is 814 610 HUF (€3256) per life year saved. Sensi-
tivity analyses shows that results are more sensitive to
discount rate and survival data and less sensitive to costs
of atherothrombotic events. CONCLUSION: Clopido-
grel is shown to be extremely cost-effective strategy in
Hungary when ASA is not a relevant alternative.
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